HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Non-Current Assets (2015 - 2026)

HUTCHMED (China)'s (HMDCF) quarterly Non-Current Assets came in at $183.0 million in Q2 2026, up 178.87% year-over-year from $65.6 million in Q2 2025, and up 176.83% quarter-over-quarter from $66.1 million in Q4 2025.

Analysis

HUTCHMED (China) (HMDCF) Non-Current Assets (2015 - 2026) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Non-Current Assets for 12 consecutive years, with $183.0 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Non-Current Assets rose 178.87% year-over-year to $183.0 million in Q2 2026; TTM through Jun 2026 was $763.9 million, a 1064.01% increase from a year earlier, with the FY2025 full-year figure at $66.1 million, down 2.15% from the prior year.
  • Non-Current Assets was $183.0 million for Q2 2026 at HUTCHMED (China), up from $66.1 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $207.0 million in Q2 2023 and troughed at $65.6 million in Q2 2025.
  • A 5-year average of $99.7 million and a median of $73.9 million in 2023 frame the typical range for Non-Current Assets.
  • Across the five-year window, Non-Current Assets tumbled 66.52% in 2024 and soared 178.87% in 2026, its largest moves.
  • Over 5 years, Non-Current Assets stood at $80.1 million in 2022, then slipped by 7.65% to $73.9 million in 2023, then retreated by 8.63% to $67.6 million in 2024, then decreased by 2.15% to $66.1 million in 2025, then soared by 176.83% to $183.0 million in 2026.
  • The last three Non-Current Assets figures came in at $183.0 million (Q2 2026), $66.1 million (Q4 2025), and $65.6 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 211.28 Bn 197.29 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 181.28 Bn 178.10 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 132.26 Bn 124.41 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 82.58 Bn 74.58 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 61.67 Bn 56.48 Bn 1.37 Bn 1.96 Bn
6 Moderna 54.58 Bn 49.44 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 34.01 Bn 30.70 Bn 992.69 Mn 938.60 Mn
8 Biogen 31.26 Bn 29.98 Bn 1.96 Bn 24.78 Bn
9 Roivant Sciences 29.78 Bn 29.78 Bn 1.16 Mn 564.41 Mn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - 183.02 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 183.02 Mn
Dec 31, 2025 66.11 Mn
Jun 30, 2025 65.63 Mn
Dec 31, 2024 67.56 Mn
Jun 30, 2024 69.31 Mn
Dec 31, 2023 73.94 Mn
Jun 30, 2023 207.01 Mn
Dec 31, 2022 80.06 Mn
Jun 30, 2022 84.97 Mn
Dec 31, 2021 91.61 Mn
Jun 30, 2021 93.36 Mn
Mar 31, 2021 196.89 Mn
Dec 31, 2020 95.73 Mn
Jun 30, 2020 91.43 Mn
Dec 31, 2019 95.10 Mn
Sep 30, 2019 177.01 Mn
Jun 30, 2019 185.72 Mn
Mar 31, 2019 189.30 Mn
Dec 31, 2018 100.35 Mn
Jun 30, 2018 183.27 Mn